JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 244 products of "JAK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
1,2,3,4,5,6-Hexabromocyclohexane
CAS:Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.Formula:C6H6Br6Purity:98%Color and Shape:SolidMolecular weight:557.54OICR-0547
CAS:OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.Formula:C28H29F3N4O4Purity:98%Color and Shape:SolidMolecular weight:542.55INCB16562
CAS:INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.Formula:C19H11Cl2N5Color and Shape:SolidMolecular weight:380.23JAK3-IN-9
CAS:JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.Formula:C17H23N5O4SColor and Shape:SolidMolecular weight:393.46TUL01101
CAS:TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.Formula:C22H25F2N5O2Color and Shape:SolidMolecular weight:429.46CP-690550A
CAS:Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36GDC-4379
CAS:GDC-4379 is a JAK1 inhibitor that can be used to study asthma.Formula:C21H18ClF2N7O3Color and Shape:SolidMolecular weight:489.86Peficitinib hydrobromide
CAS:Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.Formula:C18H23BrN4O2Color and Shape:SolidMolecular weight:407.312Povorcitinib
CAS:Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).Formula:C23H22F5N7OColor and Shape:SolidMolecular weight:507.469(2R,5S)-Ritlecitinib
CAS:(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].Formula:C15H19N5OColor and Shape:SolidMolecular weight:285.34TYK2-IN-11
CAS:TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42Thi-DPPY
CAS:Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.Formula:C28H28ClN5O4SColor and Shape:SolidMolecular weight:566.07PF-00956980
CAS:PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.Formula:C18H26N6OColor and Shape:SolidMolecular weight:342.44SYK/JAK-IN-1
CAS:SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.Formula:C24H26N8O3Color and Shape:SolidMolecular weight:474.52JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Formula:C26H30ClN7O2Color and Shape:SolidMolecular weight:508.02AC430
CAS:AC430, a specific JAK2 inhibitor for cancer and autoimmune therapy, excels in preclinical trials with low doses. Developed by Ambit.Formula:C19H16FN5OColor and Shape:SolidMolecular weight:349.36JAK-IN-21
CAS:JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.Formula:C19H16N8OPurity:99.87%Color and Shape:SolidMolecular weight:372.38JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Formula:C20H18FN5O3SPurity:99.53%Color and Shape:SolidMolecular weight:427.45Ref: TM-T13571
1mg82.00€5mg167.00€10mg246.00€25mg405.00€50mg572.00€100mg772.00€500mg1,539.00€1mL*10mM (DMSO)178.00€JAK-IN-28
CAS:JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Formula:C20H18ClN7OPurity:98%Color and Shape:SolidMolecular weight:407.86JAK-IN-30
CAS:JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50Formula:C19H26N8SPurity:98%Color and Shape:SolidMolecular weight:398.53JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formula:C26H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:521.59JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.
Formula:C25H32N8O2Purity:99.64% - 99.87%Color and Shape:SolidMolecular weight:476.57Lorpucitinib
CAS:Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.Formula:C22H28N6O2Purity:99.72%Color and Shape:SolidMolecular weight:408.5JAK3i
CAS:JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.Formula:C18H15FN4O3Purity:98.61% - 99.81%Color and Shape:SolidMolecular weight:354.34Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Formula:C12H12N4O5Color and Shape:SolidMolecular weight:292.25Butyzamide
CAS:Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.
Formula:C29H32Cl2N2O5SPurity:99.51% - 99.83%Color and Shape:SoildMolecular weight:591.55Ref: TM-T67894
1mg158.00€5mg266.00€10mg393.00€25mg605.00€50mg909.00€100mg1,378.00€200mg1,853.00€1mL*10mM (DMSO)346.00€Izencitinib
CAS:Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.Formula:C22H26N8Purity:99.82%Color and Shape:SolidMolecular weight:402.50Ref: TM-T35898
1mg84.00€5mg177.00€10mg281.00€25mg567.00€50mg888.00€100mg1,431.00€200mg1,963.00€1mL*10mM (DMSO)195.00€STS-E412
CAS:STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.Formula:C15H15ClN4O2Purity:99.01%Color and Shape:SolidMolecular weight:318.76JAK-STAT-IN-1
CAS:JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.Formula:C21H21N5O2Purity:99.59%Color and Shape:SolidMolecular weight:375.42JAK1-IN-8
CAS:JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).
Formula:C22H23FN4O3SPurity:98.4%Color and Shape:SolidMolecular weight:442.51Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521JAK-IN-17
"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."Formula:C33H38F2N6O8Color and Shape:SolidMolecular weight:684.69TCS 21311
CAS:TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.Formula:C27H25F3N4O4Purity:99.39% - ≥98%Color and Shape:SolidMolecular weight:526.51Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39Ref: TM-T78207
1mg50.00€5mg104.00€10mg167.00€25mg340.00€50mg505.00€100mg712.00€200mg1,009.00€1mL*10mM (DMSO)114.00€Tyk2-IN-9
CAS:Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41Nezulcitinib
CAS:Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurity:99.82%Color and Shape:SolidMolecular weight:389.4Ref: TM-TQ0010
1mg34.00€2mg46.00€5mg66.00€10mg99.00€25mg205.00€50mg371.00€100mg595.00€200mg833.00€1mL*10mM (DMSO)73.00€JAK-IN-5
CAS:JAK-IN-5 is a JAK inhibitor.Formula:C27H31FN6OPurity:98.1% - 99.37%Color and Shape:SolidMolecular weight:474.57Ref: TM-T11710
1mg177.00€5mg370.00€10mg552.00€25mg879.00€50mg1,189.00€100mg1,603.00€500mg3,205.00€1mL*10mM (DMSO)537.00€Ginsenoside Rk1
CAS:Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.Formula:C42H70O12Purity:98.46% - 99.13%Color and Shape:SolidMolecular weight:767.00ABBV-712
CAS:ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases
Formula:C24H28N4O5Purity:98%Color and Shape:SolidMolecular weight:452.5NMS-P953
CAS:NMS-P953: JAK2 inhibitor, reduces tumor growth in SET-2 model, confirmed in vivo action, good pharmacokinetics and safety.Formula:C16H11ClF3N5OColor and Shape:SolidMolecular weight:381.74JAK-IN-25
CAS:JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Formula:C19H17N5O4Purity:98%Color and Shape:SolidMolecular weight:379.37JAK2-IN-4
CAS:JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.Formula:C23H27N5O4SPurity:98%Color and Shape:SolidMolecular weight:469.56JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44Tubulin/JAK2-IN-1
CAS:Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significantFormula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43TCJL37
CAS:TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74JAK-IN-4
CAS:JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341JAK-IN-26
CAS:JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency inFormula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Formula:C17H19F2N7OSPurity:98%Color and Shape:SolidMolecular weight:407.44JAK-IN-31
CAS:JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Formula:C21H19N7O2S2Purity:98%Color and Shape:SolidMolecular weight:465.55
